Barclays PLC Increases Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Barclays PLC lifted its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 323.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,560 shares of the company’s stock after acquiring an additional 6,538 shares during the quarter. Barclays PLC’s holdings in Greenwich LifeSciences were worth $123,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $117,000. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences in the 2nd quarter valued at approximately $264,000. Finally, State Street Corp lifted its stake in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after buying an additional 3,005 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Stock Performance

GLSI stock opened at $13.35 on Thursday. Greenwich LifeSciences, Inc. has a 1 year low of $8.00 and a 1 year high of $21.44. The stock’s 50 day moving average price is $13.15 and its 200 day moving average price is $14.13. The firm has a market cap of $175.49 million, a P/E ratio of -16.69 and a beta of 1.66.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 3,200 shares of the business’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $11.12 per share, for a total transaction of $35,584.00. Following the acquisition, the chief executive officer now owns 5,539,302 shares of the company’s stock, valued at approximately $61,597,038.24. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have purchased 8,000 shares of company stock valued at $97,184. 51.67% of the stock is owned by corporate insiders.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.